{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever greater than 38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes \\>20%.\n\nAML, ALL \\>5% marrow blasts by morphologic or flow cytometric, or appearance of extramedullary disease.\n\nCLL ≥1 of: Physical exam/Imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.\n\nNHL \\>25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.\n\nMM\n\n≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"OG000","title":"Dose Level 1 (No Campath)"},{"description":"Patients receive alemtuzumab IV over 6 hours once daily on days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nAlemtuzumab: Given IV\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"OG001","title":"Dose Level 2 (40mg Total Dose Campath)"},{"description":"Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nAlemtuzumab: Given IV\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"OG002","title":"Dose Level 3 (60mg Total Dose Campath)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Disease Progression/Relapse","type":"SECONDARY","unitOfMeasure":"percentage of participants"}